FeaturedHealth & Education

Scientists find a better way to treat gout

- Advertisement -

Gout is caused by the accumulation of urate crystals in the joints, and xanthine oxidase inhibitors such as febuxostat are a staple treatment to help lower blood urate levels in afflicted people. However, a new clinical trial reported in Arthritis & Rheumatology suggests that benzbromarone, a less popular medication, may be better in low dosages.

In the prospective single-center, open-labeled trial, 196 men with gout and poor uric acid excretion were randomized to receive either low-dose benzbromarone (LDBen) or low-dose febuxostat (LDFeb) for 12 weeks.

See also  Researchers discover world's first 'pregnant mummy'

Compared to the LDFeb group, more individuals in the LDBen group met the blood urate objective of 6 mg/dL (32% vs 61%). There was no major difference in side effects across the groups.

“The results suggest that low dosing of benzbromarone may warrant stronger consideration as a safe and effective therapy to achieve serum urate target in gout,” the authors wrote.



- Advertisement -

Related Articles

Back to top button